var data={"title":"Dextran: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dextran: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6005?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dextran-drug-information\" class=\"drug drug_general\">see &quot;Dextran: Drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158641\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>LMD in D5W;</li>\n      <li>LMD in NaCl</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50643263\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>LMD in D5W; LMD in NaCl</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052075\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Plasma Volume Expander</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052068\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=dextran-drug-information\" class=\"drug drug_general\">see &quot;Dextran: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, Adolescents: <b>Note:</b> Dose and infusion rate are dependent upon the patient's fluid status and must be individualized: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Volume expansion/shock:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: Infuse 5 mL/kg as rapidly as necessary; maximum daily dose: 20 mL/kg/<b>day</b> for first 24 hours, 10 mL/kg/<b>day</b> thereafter; therapy should not be continued beyond 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &lt;50 kg: Infuse 10 mL/kg as rapidly as necessary; maximum daily dose: 20 mL/kg/<b>day</b> for first 24 hours, 10 mL/kg/<b>day</b> thereafter; therapy should not be continued beyond 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;50 kg: Infuse 500-1000 mL (~10 mL/kg) as rapidly as necessary; maximum daily dose: 20 mL/kg/<b>day</b> for first 24 hours; 10 mL/kg/<b>day</b> thereafter; therapy should not be continued beyond 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pump prime:</b> IV:<b> Note:</b> Dose will vary with the volume of the pump oxygenator; doses usually added to the perfusion circuit.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 5 mL/kg; usual maximum total dose: 20 mL/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 10 mL/kg; usual maximum total dose: 20 mL/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: 10-20 mL/kg; usual maximum total dose: 20 mL/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative prophylaxis of venous thrombosis/pulmonary embolism: </b> IV: <b>Note:</b> Current ACCP guidelines for the prevention of venous thromboembolism in surgical patients do not recommend the use of dextran; consider the use of other anticoagulants (Falck-Ytter, 2012; Gould, 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: Begin during surgical procedure and give 5 mL/kg; continue daily for 2-3 days; an additional 5 mL/kg should be administered every 2-3 days during the period of risk (up to 2 weeks postoperatively)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (&lt;50 kg): Begin during surgical procedure and give 10 mL/kg; continue daily for 2-3 days; an additional 10 mL/kg should be administered every 2-3 days during the period of risk (up to 2 weeks postoperatively)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents (&ge;50 kg): IV: Begin during surgical procedure and give 500-1000 mL (~10 mL/kg); an additional 500 mL should be administered every 2-3 days during the period of risk (up to 2 weeks postoperatively)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Volume expansion/shock:</b> IV: Infuse 500-1000 mL (~10 mL/kg) as rapidly as possible; maximum: 20 mL/kg/day for first 24 hours; 10 mL/kg/day thereafter; therapy should not be continued beyond 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pump prime:</b> IV: Varies with the volume of the pump oxygenator; generally, the solution is added in a dose of 10-20 mL/kg; usual maximum total dose: 20 mL/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative prophylaxis of venous thrombosis/pulmonary embolism:</b> IV: <b>Note: </b>Current ACCP guidelines for the prevention of venous thromboembolism in surgical patients do not recommend the use of dextran; consider the use of other anticoagulants (Falck-Ytter, 2012; Gould, 2012): Per the manufacturer, begin during surgical procedure and give 500-1000 mL (~10 mL/kg); continue treatment with 500 mL once daily for 2-3 additional days. Additional 500 mL should be administered every 2-3 days during the period of risk (up to 2 weeks postoperatively).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158627\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LMD in D5W: 10% Dextran 40 (500 mL) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LMD in NaCl: 10% Dextran 40 (500 mL) [latex free]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158613\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052078\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Do not use if crystalline precipitate forms. For IV infusion only (use an infusion pump or pressure infusion). For volume expansion/shock, may infuse initial volume as rapidly as possible. <b>Monitor closely for anaphylactic reaction; have epinephrine and resuscitative equipment available</b>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158637\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze. Do not use if crystalline precipitate forms. Discard partially used containers. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052077\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunctive treatment of shock or impending shock due to trauma (eg, burns, hemorrhage, surgery, surgical complications), a priming fluid in pump oxygenators during extracorporeal circulation, and for venous thrombosis and pulmonary embolism prophylaxis in patients undergoing surgery associated with a high incidence of thromboembolic complications (eg, hip surgery) (All indications: FDA approved in infants, children, adolescents, and adults), <b>Note:</b> This is not a substitute for blood or plasma; does not have oxygen-carrying capacity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158683\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dextran may be confused with Dexedrine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158680\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest tightness, hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Prolonged bleeding time (dose-related), wound hemorrhage (dose-related), wound hematoma (dose-related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal liver function tests</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pulmonary edema (dose-related), wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158632\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to dextran or any component of the formulation; marked hemostatic defects (eg, thrombocytopenia, hypofibrinogenemia) of all types including those caused by medications (eg, heparin, warfarin); marked cardiac decompensation; renal disease with severe oliguria or anuria </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158617\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fluid overload: Administration may cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young, elderly patients, or those with heart failure).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic: Large volumes of dextran (doses &gt;1000 mL) may cause reduction in hemoglobin concentration and excessive dilution of plasma proteins due to hemodilution; transient prolongation of bleeding time or an increase in bleeding tendency may occur with large volumes; use caution to prevent a decrease in hematocrit &lt;30%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Severe and fatal anaphylactoid reactions have been reported; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy.   </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal failure: Has been reported with use; fluid status including urine output should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart failure: Use with caution in heart failure patients; monitor closely for fluid overload.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemorrhage: Use with caution in patients with active hemorrhage;. may increase the risk of more bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; fluid status including urine output should be monitored closely. Excessive dosing may precipitate renal failure in patients with advanced renal disease. Use in severe oliguria or anuria is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombocytopenia: Use with caution in patients with thrombocytopenia; doses &gt;1000 mL may interfere with platelet function and transiently prolong bleeding time. Observe for bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Not a substitute for blood or blood components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299161\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1076314\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13217&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abciximab: Dextran may enhance the anticoagulant effect of Abciximab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: Dextran may enhance the nephrotoxic effect of Arbekacin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Dextran may enhance the anticoagulant effect of Desirudin. More specifically, dextran may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with dextran prior to desirudin initiation when possible.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158623\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14446431\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052074\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs, signs of allergic/anaphylactoid reaction especially for 30 minutes after starting infusions; coagulation parameters, hemoglobin, hematocrit, acid-base balance, electrolytes, serum protein, signs of circulatory overload (ie, heart rate, blood pressure, central venous pressure, hematocrit), renal function, urine output; urine specific gravity; platelets </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158616\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Produces plasma volume expansion by virtue of its highly colloidal starch structure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158631\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Plasma expanding effect lasts 3-4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~75%) within 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323102\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LMD in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-5% (500 mL): $31.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LMD in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-0.9% (500 mL): $32.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158634\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dekstran 40000 (PL);</li>\n      <li>Dekstran 70000 (PL);</li>\n      <li>Deltadex (GR);</li>\n      <li>Dextran 40 (DE, JO, LT, LV, PT, QA);</li>\n      <li>Dextran 40 Injection (AU);</li>\n      <li>Dextran 70 (DE, JO, QA);</li>\n      <li>Dextran 70 Injection (AU);</li>\n      <li>Gentran (GR);</li>\n      <li>Gentran 40 (LU);</li>\n      <li>Gentran 70 (LU);</li>\n      <li>LM Dextran (PH);</li>\n      <li>Longasteril 40&deg; (LU);</li>\n      <li>Macrodex 10% (DK);</li>\n      <li>Plander (IT);</li>\n      <li>Plasmex (IN);</li>\n      <li>Rheomacrodex (EG, LU, NO, SE);</li>\n      <li>Soludeks 40 (HR);</li>\n      <li>Soludeks 70 (HR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(Suppl 2) e278S-325S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextran-pediatric-drug-information/abstract-text/22315265/pubmed\" target=\"_blank\" id=\"22315265\">22315265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):e227-277.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextran-pediatric-drug-information/abstract-text/22315263/pubmed\" target=\"_blank\" id=\"22315263\">22315263</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13217 Version 76.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F158641\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50643263\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1052075\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1052068\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F158627\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F158613\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1052078\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F158637\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1052077\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F158683\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F158680\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F158632\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F158617\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299161\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F1076314\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F158623\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14446431\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1052074\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F158616\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F158631\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323102\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F158634\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13217|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dextran-drug-information\" class=\"drug drug_general\">Dextran: Drug information</a></li></ul></div></div>","javascript":null}